Switch theme
Sign up to access all valuation multiples
Eucalia Inc is engaged in total medical management support, Operation of nursing care homes & Total support business for senior life, medical equipment business, etc.
2005
n/a
LTM Revenue $139M
LTM EBITDA $24.9M
$309M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Eucalia has a last 12-month revenue of $139M and a last 12-month EBITDA of $24.9M.
In the most recent fiscal year, Eucalia achieved revenue of $132M and an EBITDA of $29.6M.
Eucalia expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Eucalia valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $120M | $132M | XXX | XXX | XXX |
| Gross Profit | $38.6M | $47.2M | XXX | XXX | XXX |
| Gross Margin | 32% | 36% | XXX | XXX | XXX |
| EBITDA | $19.2M | $29.6M | XXX | XXX | XXX |
| EBITDA Margin | 16% | 22% | XXX | XXX | XXX |
| Net Profit | $6.5M | $7.0M | XXX | XXX | XXX |
| Net Margin | 5% | 5% | XXX | XXX | XXX |
| Net Debt | $58.8M | $98.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Eucalia's stock price is JPY 979 (or $7).
Eucalia has current market cap of JPY 34.6B (or $230M), and EV of JPY 46.5B (or $309M).
See Eucalia trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $309M | $230M | XXX | XXX | XXX | XXX | $0.45 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Eucalia has market cap of $230M and EV of $309M.
Eucalia's trades at 2.2x LTM EV/Revenue multiple, and 12.4x LTM EBITDA.
Analysts estimate Eucalia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Eucalia and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $309M | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 10.4x | XXX | XXX | XXX |
| P/E | 17.1x | XXX | XXX | XXX |
| P/E/Growth | 1.0x | XXX | XXX | XXX |
| EV/FCF | -884.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEucalia's NTM/LTM revenue growth is 17%
Eucalia's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Eucalia's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Eucalia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Eucalia and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 22% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 54% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 39% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 32% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Alcidion Group | XXX | XXX | XXX | XXX | XXX | XXX |
| PharmX Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| CompuGroup Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| BIT Computer | XXX | XXX | XXX | XXX | XXX | XXX |
| ezCaretech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eucalia acquired XXX companies to date.
Last acquisition by Eucalia was XXXXXXXX, XXXXX XXXXX XXXXXX . Eucalia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Eucalia founded? | Eucalia was founded in 2005. |
| Where is Eucalia headquartered? | Eucalia is headquartered in Japan. |
| Is Eucalia publicy listed? | Yes, Eucalia is a public company listed on TKS. |
| What is the stock symbol of Eucalia? | Eucalia trades under 286A ticker. |
| When did Eucalia go public? | Eucalia went public in 2024. |
| Who are competitors of Eucalia? | Similar companies to Eucalia include e.g. Alcidion Group, PharmX Technologies, CompuGroup Medical, BIT Computer. |
| What is the current market cap of Eucalia? | Eucalia's current market cap is $230M |
| What is the current revenue of Eucalia? | Eucalia's last 12-month revenue is $139M. |
| What is the current EBITDA of Eucalia? | Eucalia's last 12-month EBITDA is $24.9M. |
| What is the current EV/Revenue multiple of Eucalia? | Current revenue multiple of Eucalia is 2.2x. |
| What is the current EV/EBITDA multiple of Eucalia? | Current EBITDA multiple of Eucalia is 12.4x. |
| What is the current revenue growth of Eucalia? | Eucalia revenue growth between 2023 and 2024 was 10%. |
| Is Eucalia profitable? | Yes, Eucalia is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
